Association of Age and Sex with Mortality Following Adjuvant Therapy for Renal Cancer

In this post-hoc analysis of ASSURE, the first and largest adjuvant VEGF inhibitor trial for resected renal cancer, we found increased mortality in older women treated with adjuvant sunitinib with more than 20% lower 5-year survival rates versus placebo. These findings caution that there may be subg...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2019-01, Vol.125 (10), p.1637-1644
Main Authors: Mamtani, Ronac, Wang, Xin Victoria, Gyawali, Bishal, DiPaola, Robert S, Epperson, C. Neill, Haas, Naomi B, Dutcher, Janice P
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this post-hoc analysis of ASSURE, the first and largest adjuvant VEGF inhibitor trial for resected renal cancer, we found increased mortality in older women treated with adjuvant sunitinib with more than 20% lower 5-year survival rates versus placebo. These findings caution that there may be subgroups of patients at risk of harm when an adjuvant therapy fails to improve overall survival.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.31955